Deutsche Bank AG Has $3.87 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Deutsche Bank AG reduced its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 24.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 350,614 shares of the company's stock after selling 111,861 shares during the period. Deutsche Bank AG owned about 0.66% of Stoke Therapeutics worth $3,867,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of STOK. China Universal Asset Management Co. Ltd. acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $124,000. Rhumbline Advisers boosted its holdings in shares of Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after purchasing an additional 2,787 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Stoke Therapeutics by 8.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company's stock valued at $3,774,000 after acquiring an additional 25,995 shares in the last quarter. Finally, Swiss National Bank increased its stake in Stoke Therapeutics by 20.4% during the 4th quarter. Swiss National Bank now owns 67,300 shares of the company's stock worth $742,000 after buying an additional 11,400 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on STOK shares. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Chardan Capital reissued a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. HC Wainwright reduced their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $23.20.

Stoke Therapeutics Trading Down 1.5%

STOK stock traded down $0.14 on Friday, hitting $9.36. 471,276 shares of the company's stock traded hands, compared to its average volume of 712,129. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58. The stock has a market cap of $511.03 million, a price-to-earnings ratio of -4.46 and a beta of 1.20. The stock has a fifty day moving average of $8.26 and a 200-day moving average of $9.82.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock worth $143,332 over the last 90 days. 11.30% of the stock is owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.